Pernix Therapeutics PTX and
Somaxon Pharmaceuticals, Inc. (“Somaxon”) SOMX today announced
that they have entered into a definitive merger agreement for Pernix to
acquire Somaxon in a stock-for-stock transaction with a total equity
value of $25 million.
Under the terms of the agreement, which has been unanimously approved by
the boards of directors of both companies, Somaxon stockholders will
receive aggregate consideration equal to $25 million in Pernix common
stock. The number of shares of Pernix common stock to be issued to the
stockholders of Somaxon will be based on the volume-weighted average
price of Pernix's common stock over the 30 day period ending on the day
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in